Ana Carolina Zattar

• Represented Versanis Bio, Inc. in its merger with Eli Lilly and Company
• Represented Rosemont Pharmaceuticals Limited in its acquisition of Sabal Therapeutics, LLC and its affiliates
• Represented UPL Corp in the acquisition of Corteva’s solo formulation mancozeb global fungicide business
• Represented Alkermes plc in its cross-border spin-off of its oncology business, Mural Oncology plc
• Represented ETM-Electromatic, Inc. in its merger with Teledyne Digital Imaging US, Inc.
• Represented Brahma Therapeutics, Inc. in its merger with Myeloid Therapeutics, Inc.
• Represented Sovos Compliance, LLC, HG Capital-backed leading global provider of software, in the acquisition of several companies in Brazil in order to start and expand its activities in Brazil*
• Represented Hertz in the sale of its Brazilian subsidiary to Localiza, one of the major car rentals companies in Brazil, as well as in the negotiation of the agreements for the use of a combined mark of Hertz Localiza in Brazil*
• Represented Claro S.A., one of the Brazil’s largest mobile operators, in the acquisition, together with the other 2 major mobile operators in Brazil, of the mobile telephone business of Oi*
• Represented the Brazilian subsidiary of Orpea SA in the increase of its equity participation in a Brazil-based elderly care provider joint venture with Patria Investimentos*
• Represented Onex Corp and Baring Private Equity Asia in the Brazilian part of the deal involving the acquisition of the intellectual property and science business of Thomson Reuters*
• Represented S.C. Johnson & Son Inc., Ceras Johnson Ltda. and SCJohnson Distribuição Ltda. in the assignment and transfer of some of its assets to Bombril Mercosul S.A. and Bombril S.A*
• Represented Crescera Capital and Seek International Investments Pty. Ltd. in the acquisition of a majority stake in Alura, a leading company focused on educational services in the technology sector in Brazil*
• Represented Crescera Capital (formerly Bozano Investimentos) in the acquisition of a minority equity interest in Uniceplac, a university based on the Federal District of Brazil*

• Represented Nested Therapeutics, Inc. in its Series A Preferred Stock financing
• Represented Forward Therapeutics, Inc. in its Series A Preferred Stock financing
• Represented Brahma Therapeutics, Inc. in its Series A Preferred Stock financing
• Represented Arix Bioscience Holdings Limited in its investment in the Series B Preferred Stock financing of Evommune, Inc.

• Represented Monte Rosa Therapeutics, Inc. in its $100 million follow on offering
• Represented Cabaletta Bio, Inc. in its $100 million follow on offering
• Represented Monte Rosa Therapeutics, Inc. in its registered direct offering of approximately $25 million
• Represented Cabaletta Bio, Inc. in its registered direct offering of approximately $35 million
• Represented Cabaletta Bio, Inc. in its $100 million and $200 million at-the-market offerings

• Represented C4 Therapeutics, Inc. in its exclusive licensing arrangement with Betta Pharmaceuticals Co. Ltd
• Advised GlaxoSmithKline in the joint venture formed with Novartis in relation to the consumer healthcare business in Brazil*
• Advised Vodafone in meetings and talks before Brazilian National Telecom Agency (ANATEL) regarding the implementation of projects related to Internet of Things in Brazil*
• Advised AT&T in the public consultation made by the Brazilian National Telecom Agency (ANATEL) regarding the possible regulation or deregulation of the Internet of Things*

*Denotes experience prior to joining Goodwin.